39 related articles for article (PubMed ID: 21244753)
1. GW0742, a high affinity PPAR-β/δ agonist reduces lung inflammation induced by bleomycin instillation in mice.
Galuppo M; Di Paola R; Mazzon E; Esposito E; Paterniti I; Kapoor A; Thiemermann C; Cuzzocrea S
Int J Immunopathol Pharmacol; 2010; 23(4):1033-46. PubMed ID: 21244753
[TBL] [Abstract][Full Text] [Related]
2. PPARβ/δ-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1ΔE9 astrocytes.
Konttinen H; Gureviciene I; Oksanen M; Grubman A; Loppi S; Huuskonen MT; Korhonen P; Lampinen R; Keuters M; Belaya I; Tanila H; Kanninen KM; Goldsteins G; Landreth G; Koistinaho J; Malm T
Glia; 2019 Jan; 67(1):146-159. PubMed ID: 30453390
[TBL] [Abstract][Full Text] [Related]
3. Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals.
Niu HS; Ku PM; Niu CS; Cheng JT; Lee KS
Drug Des Devel Ther; 2015; 9():5625-32. PubMed ID: 26508837
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease.
Gonzales J; Fraidenburg DR
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986517
[TBL] [Abstract][Full Text] [Related]
5. Beneficial Impacts of Alpha-Eleostearic Acid from Wild Bitter Melon and Curcumin on Promotion of CDGSH Iron-Sulfur Domain 2: Therapeutic Roles in CNS Injuries and Diseases.
Kung WM; Lin MS
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33804820
[TBL] [Abstract][Full Text] [Related]
6. The NFκB Antagonist CDGSH Iron-Sulfur Domain 2 Is a Promising Target for the Treatment of Neurodegenerative Diseases.
Kung WM; Lin MS
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477809
[TBL] [Abstract][Full Text] [Related]
7. Wild Bitter Melon Exerts Anti-Inflammatory Effects by Upregulating Injury-Attenuated CISD2 Expression following Spinal Cord Injury.
Kung WM; Lin CC; Kuo CY; Juin YC; Wu PC; Lin MS
Behav Neurol; 2020; 2020():1080521. PubMed ID: 33062068
[TBL] [Abstract][Full Text] [Related]
8. Adelmidrol: A New Promising Antioxidant and Anti-Inflammatory Therapeutic Tool in Pulmonary Fibrosis.
Fusco R; Cordaro M; Genovese T; Impellizzeri D; Siracusa R; Gugliandolo E; Peritore AF; D'Amico R; Crupi R; Cuzzocrea S; Di Paola R
Antioxidants (Basel); 2020 Jul; 9(7):. PubMed ID: 32660140
[TBL] [Abstract][Full Text] [Related]
9. Thymic stromal lymphopoietin protects in a model of airway damage and inflammation via regulation of caspase-1 activity and apoptosis inhibition.
Shubin NJ; Clauson M; Niino K; Kasprzak V; Tsuha A; Guga E; Bhise G; Acharya M; Snyder JM; Debley JS; Ziegler SF; Piliponsky AM
Mucosal Immunol; 2020 Jul; 13(4):584-594. PubMed ID: 32103153
[TBL] [Abstract][Full Text] [Related]
10. Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases.
Liu F; Bayliss G; Zhuang S
Clin Sci (Lond); 2019 Jun; 133(12):1309-1320. PubMed ID: 31217321
[TBL] [Abstract][Full Text] [Related]
11. Discovering highly selective and diverse PPAR-delta agonists by ligand based machine learning and structural modeling.
Da'adoosh B; Marcus D; Rayan A; King F; Che J; Goldblum A
Sci Rep; 2019 Jan; 9(1):1106. PubMed ID: 30705343
[TBL] [Abstract][Full Text] [Related]
12. PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma.
Banno A; Reddy AT; Lakshmi SP; Reddy RC
Nucl Receptor Res; 2018; 5():. PubMed ID: 29450204
[TBL] [Abstract][Full Text] [Related]
13. Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Duncan G; Firth K; George V; Hoang MD; Staniforth A; Smith G; Denning C
Stem Cells Dev; 2017 Dec; 26(23):1695-1705. PubMed ID: 28992755
[TBL] [Abstract][Full Text] [Related]
14. PPAR-δ Agonist With Mesenchymal Stem Cells Induces Type II Collagen-Producing Chondrocytes in Human Arthritic Synovial Fluid.
Heck BE; Park JJ; Makani V; Kim EC; Kim DH
Cell Transplant; 2017 Aug; 26(8):1405-1417. PubMed ID: 28901183
[TBL] [Abstract][Full Text] [Related]
15. Novel Anti-fibrotic Therapies.
McVicker BL; Bennett RG
Front Pharmacol; 2017; 8():318. PubMed ID: 28620300
[TBL] [Abstract][Full Text] [Related]
16. Induced Pluripotent Stem Cells Inhibit Bleomycin-Induced Pulmonary Fibrosis in Mice through Suppressing TGF-β1/Smad-Mediated Epithelial to Mesenchymal Transition.
Zhou Y; He Z; Gao Y; Zheng R; Zhang X; Zhao L; Tan M
Front Pharmacol; 2016; 7():430. PubMed ID: 27895584
[TBL] [Abstract][Full Text] [Related]
17. PPARβ/δ selectively regulates phenotypic features of age-related macular degeneration.
Choudhary M; Ding JD; Qi X; Boulton ME; Yao PL; Peters JM; Malek G
Aging (Albany NY); 2016 Sep; 8(9):1952-1978. PubMed ID: 27622388
[TBL] [Abstract][Full Text] [Related]
18. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
Ruzehaji N; Frantz C; Ponsoye M; Avouac J; Pezet S; Guilbert T; Luccarini JM; Broqua P; Junien JL; Allanore Y
Ann Rheum Dis; 2016 Dec; 75(12):2175-2183. PubMed ID: 26961294
[TBL] [Abstract][Full Text] [Related]
19. The Antifibrosis Effects of Peroxisome Proliferator-Activated Receptor δ on Rat Corneal Wound Healing after Excimer Laser Keratectomy.
Gu Y; Li X; He T; Jiang Z; Hao P; Tang X
PPAR Res; 2014; 2014():464935. PubMed ID: 25477952
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor-β/δ regulates angiogenic cell behaviors and oxygen-induced retinopathy.
Capozzi ME; McCollum GW; Savage SR; Penn JS
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):4197-207. PubMed ID: 23716627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
